Other languages Daré Bioscience, Inc.

Equities

DARE

US23666P1012

Real-time Estimate Cboe BZX Other stock markets 03:04:06 2024-05-13 pm EDT			5-day change	1st Jan Change
0.315 ^USD	+1.45%		+2.39%	+1.39%

Apr. 30	Daré Bioscience, Inc. Closes Royalty Monetization Transaction with XOMA (US) LLC	CI
Apr. 30	XOMA Corporation completed the acquisition of three First-in-Category Assets of Daré Bioscience, Inc. for $22 million.	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Daré Bioscience, Inc. Closes Royalty Monetization Transaction with XOMA (US) LLC	Apr. 30
XOMA Corporation completed the acquisition of three First-in-Category Assets of Daré Bioscience, Inc. for $22 million.	Apr. 29
Daré Bioscience, Inc. Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1	Apr. 23
Daré Bioscience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28
Daré Bioscience, Inc. Announces Positive End-Of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024	Jan. 31
Daré Bioscience, Inc. Announces Executive Changes	Jan. 26
Dare Bioscience Says Chief Financial Officer Retiring, Chief Commercial Officer Has Resigned	Jan. 26
Dare Bioscience, Inc. Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the Dare-Pdm1 Phase 1 Clinical Study	Dec. 20
Dare Bioscience Obtains FDA Clearance for Phase 2 Trial of Potential Dyspareunia Treatment	Dec. 07
Dare Bioscience, Inc. Announces FDA Clearance of Investigational New Drug Application for DARE-VVA1	Dec. 07
Dare Bioscience, Inc. Announces Commencement of Phase 3 Study of Ovaprene, an Investigational Hormone-Free Monthly Intravaginal Contraceptive	Dec. 04
Dare Bioscience Extends Agreement With Premier Research to Advance Reproductive Health Portfolio	Nov. 20
Dar Bioscience, Inc. and Premier Research International LLC Extend Strategic Partnership to Accelerate the Clinical Development of Dar's Novel Women's Health Programs	Nov. 20
Daré Bioscience, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2023	Nov. 09
Dare Bioscience Says Additional Data Show Sildenafil Cream Improving Sexual Disorder Symptoms	Nov. 01
Sector Update: Health Care Stocks Rise Late Afternoon	23-10-16
Sector Update: Health Care Stocks Gaining Monday Afternoon	23-10-16
Dare Bioscience Triggers $1.8 Million Milestone Payment from Organon With Xaciato's First Shipment	23-10-16
Dare Bioscience to Get $4.5 Million Grant Funding Installment for Development of Contraceptive Technology	23-09-21
Dare Bioscience to Raise $7 Million in Registered Direct Offering of Shares, Warrants	23-08-30

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Daré Bioscience, Inc.

Equities

DARE

US23666P1012

Other languages

Filters